A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
Status:
Terminated
Trial end date:
2010-01-19
Target enrollment:
Participant gender:
Summary
The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate
comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in
control of mild persistent asthma?
The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy
with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50,
when measured by this standard methodology (methacholine bronchoprovocation) in subjects with
mild persistent asthma.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Schering-Plough
Treatments:
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Mometasone Furoate